NCT02873962 2025-06-08A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibDana-Farber Cancer InstitutePhase 2 Active not recruiting73 enrolled
NCT03824704 2023-06-12A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)pharmaand GmbHPhase 2 Terminated1 enrolled 7 charts